GRFS logo

GRFS
Grifols, SA

917
Mkt Cap
$2.13B
Volume
138,751.00
52W High
$11.14
52W Low
$7.08
PE Ratio
12.21
GRFS Fundamentals
Price
$8.23
Prev Close
$8.24
Open
$8.23
50D MA
$8.29
Beta
0.92
Avg. Volume
760,329.33
EPS (Annual)
$0.6666
P/B
0.90
Rev/Employee
$336,187.37
$18,402.67
Loading...
Loading...
News
all
press releases
Wall Street Zen Downgrades Grifols (NASDAQ:GRFS) to Hold
Wall Street Zen cut shares of Grifols from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat·11h ago
News Placeholder
More News
News Placeholder
Grifols (GRFS) to Release Earnings on Thursday
Grifols (NASDAQ:GRFS) will be releasing its Q1 2026 earnings on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-grifols-sa-stock...
MarketBeat·9d ago
News Placeholder
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
ADMA banks on surging Asceniv demand to sustain growth, supported by expanded plasma supply and broader coverage, which should drive continued gains into 2026.
Zacks·10d ago
News Placeholder
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
ADMA stock slides after a short report sparks volatility, but management pushes back, citing strong Asceniv demand and steady fundamentals.
Zacks·16d ago
News Placeholder
Grifols, S.A. (NASDAQ:GRFS) Short Interest Update
Grifols, S.A. (NASDAQ:GRFS - Get Free Report) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totaling 5,261,576 shares, a drop of 25.0...
MarketBeat·17d ago
News Placeholder
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
ADMA stock plunges after a short report, but strong Asceniv demand, rising revenues, and margin expansion signal potential recovery ahead.
Zacks·17d ago
News Placeholder
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
ADMA rides on margin gains, supply deals, and IVIG shift into 2026, but valuation and recent stock decline add complexity for investors.
Zacks·22d ago
News Placeholder
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
ADMA rides on surging Asceniv demand, expanding payer coverage, and stronger plasma supply deals to drive rapid revenue growth through 2027.
Zacks·1mo ago
News Placeholder
Integrated Quantitative Investments LLC Buys New Holdings in Grifols, S.A. $GRFS
Integrated Quantitative Investments LLC bought a new position in Grifols, S.A. (NASDAQ:GRFS - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange...
MarketBeat·2mo ago
News Placeholder
JPMorgan Chase & Co. Has $24.78 Million Stock Holdings in Grifols, S.A. $GRFS
JPMorgan Chase & Co. raised its position in Grifols, S.A. (NASDAQ:GRFS - Free Report) by 31.8% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor...
MarketBeat·2mo ago
<
1
2
...
>

Latest GRFS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.